Phaseline

Targets › ADRB1

ADRB1 (Beta-1 adrenergic receptor): drug programs, companies and trials

113 programs from 95 companies in 128 trials: 59 Phase 4, 31 Phase 2, 22 Phase 3, 16 Phase 1; Cardiovascular, Other, Oncology; next expected readout Nov 2026.

G protein-coupled receptor for catecholamines that couples to G(s) proteins to activate adenylate cyclase and cAMP-dependent pathway. Binds epinephrine and norepinephrine with approximately equal affinity. (UniProt, P08588)

Open in Phaseline: the race on ADRB1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Yongtao SunEsmolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4FrailtyNov 2026
King's College Hospital NHS TrustCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4Cirrhosis, LiverDec 2026
Ottawa Heart Institute Research CorporationDobutamine
Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist
ADRB1, ADRB2Phase 4Shock, CardiogenicDec 2026
Cairo UniversityEphedrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Incidence of Post-spinal HypotensionDec 2026
Mansoura UniversityEphedrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Cesarean DeliveryDec 2026
Mansoura UniversityNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Cesarean DeliveryDec 2026
Damanhour Teaching HospitalAtenolol
Beta-1 adrenergic receptor antagonist
ADRB1Phase 4Hypotension Drug-InducedJan 2027
Damanhour Teaching HospitalMetoprolol
Beta-1 adrenergic receptor antagonist
ADRB1Phase 4Hypotension Drug-InducedJan 2027
Weill Medical College of Cornell UniversityMetoprolol
Beta-1 adrenergic receptor antagonist
ADRB1Phase 4Heart FailureFeb 2027
University of North Carolina, Chapel HillPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4Cardiovascular DiseaseFeb 2027
Sohag UniversityNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Patients Undergoing Orthopedic Hip Surgery Under Spinal AnesthesiaMar 2027
University of OklahomaPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4Tobacco Use DisorderMar 2027
Morten Steen Kvistholm JensenBisoprolol
Beta-1 adrenergic receptor antagonist
ADRB1Phase 4Non-obstructive Hypertrophic CardiomyopathyApr 2027
ARS PharmaceuticalsEpinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Allergic Reactions; Knee Arthroplasty, Total; Cardiac Arrest, Out-Of-Hospital; Shock Hypovolemic …Apr 2027
Icahn School of Medicine at Mount SinaiEphedrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4LaborMay 2027
Yale UniversityMetoprolol
Beta-1 adrenergic receptor antagonist
ADRB1Phase 4AnginaMay 2027
Hospital Sirio-LibanesCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4CancerMay 2027
Università Vita-Salute San RaffaeleLandiolol
Ultra-short-acting beta-1-selective adrenergic receptor antagonist
ADRB1Phase 4Cardiac FailureJun 2027
University of California, DavisDopamine
Beta-1 adrenergic receptor agonist
ADRB1Phase 4Hypotension and ShockJun 2027
James J. Peters Veterans Affairs Medical CenterDroxidopa
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4HypotensionJun 2027
University of California, DavisNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Hypotension and ShockJun 2027
TecnoquimicasPreservative-free dorzolamide-timolol-brimonidine combination
Carbonic anhydrase inhibitor (dorzolamide), beta-adrenergic antagonist (timolol), and alph
CA2, ADRB1, ADRA2APhase 4Primary Open-Angle Glaucoma (POAG)Jul 2027
Aarhus University HospitalLabetalol
Adrenergic receptor antagonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Intracerebral HaemorrhageSep 2027
Madeleine PuissantMetoprolol
Beta-1 adrenergic receptor antagonist
ADRB1Phase 4Non-Traumatic Subarachnoid HemorrhageSep 2027
University of AlbertaNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4VasoconstrictionDec 2027
Vastra Gotaland RegionBisoprolol
Beta-1 adrenergic receptor antagonist
ADRB1Phase 4Myocardial InfarctDec 2027
University Hospital, LimogesEsmolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4Laparoscopic Cholecystectomy SurgeryJan 2028
National and Kapodistrian University of AthensMetoprolol
Beta-1 adrenergic receptor antagonist
ADRB1Phase 4Aortic Valve StenosisJan 2028
Insel Gruppe AG, University Hospital BernLandiolol
Ultra-short acting beta-1 adrenergic receptor antagonist
ADRB1Phase 4Perioperative Myocardial InjuryJan 2028
Post Graduate Institute of Medical Education and Research, ChandigarhCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4Cirrhotic CardiomyopathyJan 2029
University of MichiganMetoprolol Succinate
Beta-1 adrenergic receptor antagonist
ADRB1Phase 4Heart Failure With Reduced Ejection FractionJul 2029
Taipei Veterans General Hospital, TaiwanCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4Hepatocellular Carcinoma (HCC); CirrhosisOct 2030
University of RochesterCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4Heart Failure With Reduced Ejection Fraction (HFrEF)Jun 2031
Chinese University of Hong KongCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4Portal HypertensionJul 2031
Bo Gregers WinkelAtenolol
Beta-1 adrenergic receptor antagonist
ADRB1Phase 4Idiopathic Ventricular FibrillationDec 2032
Bo Gregers WinkelBisoprolol
Beta-1 adrenergic receptor antagonist
ADRB1Phase 4Idiopathic Ventricular FibrillationDec 2032
Bo Gregers WinkelNadolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4Idiopathic Ventricular FibrillationDec 2032
Bo Gregers WinkelPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4Idiopathic Ventricular FibrillationDec 2032
National Heart Centre SingaporeMetoprolol
Beta-1 adrenergic receptor antagonist
ADRB1Phase 4Diabetes MellitusJun 2034
Bispebjerg HospitalBisoprolol
Beta-1 adrenergic receptor antagonist
ADRB1Phase 4Acute Myocardial InfarctionDec 2035
Bispebjerg HospitalCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4Acute Myocardial InfarctionDec 2035
Oslo University HospitalMetoprolol
Beta-1 adrenergic receptor antagonist
ADRB1Phase 4Acute Myocardial InfarctionDec 2035
Bispebjerg HospitalMetoprolol Succinate
Beta-1 adrenergic receptor antagonist
ADRB1Phase 4Acute Myocardial InfarctionDec 2035
Bispebjerg HospitalNebivolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4Acute Myocardial InfarctionDec 2035
Dalian Municipal Central HospitalEphedrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Hypotension Drug-Induced–
Nebraska Methodist Health SystemLabetalol
Adrenergic receptor antagonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Postpartum Preeclampsia–
VZW Cardiovascular Research Center AalstMetoprolol Tartrate
Beta-1 adrenergic receptor antagonist
ADRB1Phase 4Coronary Arterial Disease (CAD)–
Tunis UniversityNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Sepsis, Severe–
Dalian Municipal Central HospitalNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Hypotension Drug-Induced–
Hassan II UniversityNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Cesarean Section Complications–
Massachusetts General HospitalPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4Stress Disorders, Post-Traumatic–
Walter Reed Army Institute of Research (WRAIR)Propranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4Fear of Spiders–
University of Illinois ChicagoSotalol
Beta-1 adrenergic receptor antagonist; HERG blocker; Beta-2 adrenergic receptor antagonist
ADRB1, Ion channels, ADRB2Phase 4Atrial Fibrillation–
Federal University of São PauloTriplenex (triple fixed combination)
Triple combination: alpha-2 adrenergic agonist (brimonidine), non-selective beta-blocker (
ADRA2A, ADRB1, ADRB2, PTGFRPhase 4Glaucoma–
University of Texas Southwestern Medical Centermetoprolol
Beta-1 adrenergic receptor antagonist
ADRB1Phase 4Heat Stress–
University of Texas Southwestern Medical Centerpropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 4Heat Stress–
NHS Greater Glasgow and ClydeNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 3SepsisNov 2026
VA Office of Research and DevelopmentMetoprolol Succinate
Beta-1 adrenergic receptor antagonist
ADRB1Phase 3End-Stage Kidney DiseaseDec 2026
Odense University HospitalNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 3ShockDec 2026
Consorcio Centro de Investigación Biomédica en Red (CIBER)Esmolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 3CirrhosisMar 2027
Centre Hospitalier Universitaire, AmiensLandiolol
Beta-1 selective adrenergic receptor antagonist
ADRB1Phase 3Septic ShockJun 2027
Jagiellonian UniversityNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 3Blood Pressure ManagementJun 2027
Hospital do CoracaoNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 3Septic ShockAug 2027
University Hospital, BordeauxNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 3Stroke, AcuteAug 2027
University Hospital, ToulousePropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 3PTSDSep 2027
Loma Linda UniversityLabetalol
Adrenergic receptor antagonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 3Postpartum ComplicationDec 2027
Fundació d'investigació Sanitària de les Illes BalearsPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 3Traumatic Brain Injury (TBI) PatientsJun 2028
Acer TherapeuticsCeliprolol (ACER-002)
Beta-2 adrenergic receptor partial agonist; Adrenergic receptor alpha-2 antagonist; Beta-1 adrenergic receptor antagonist
ADRB2, ADRA2A, ADRA2C, ADRA2B, ADRB1Phase 3Vascular Ehlers-Danlos SyndromeMar 2029
Washington University School of MedicineBisoprolol
Beta-1 adrenergic receptor antagonist
ADRB1Phase 3Heart Failure With Reduced Ejection FractionApr 2029
Sherief Abd-ElsalamBisoprolol Fumarate
Beta-1 adrenergic receptor antagonist
ADRB1Phase 3Beta Blocker ToxicityOct 2030
SWOG Cancer Research NetworkCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 3CardiotoxicityJun 2031
Ain Shams UniversityCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 3Cardiotoxicity–
International Centre for Diarrhoeal Disease Research, BangladeshDopamine
Beta-1 adrenergic receptor agonist
ADRB1Phase 3Shock Hypovolemic–
Assistance Publique - Hôpitaux de ParisLandiolol
Selective beta-1 adrenergic receptor antagonist
ADRB1Phase 3Septic Shock–
University of Turin, ItalyNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 3Critical Illness–
Emory UniversityPropranolol Hydrochloride
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Locally Advanced Bladder Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8Dec 2026
Stanford UniversityNebivolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Angina PectorisDec 2026
Zealand University HospitalPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Pancreatic CancerDec 2026
Huashan Hospitalpropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Gastrointestinal TumorsDec 2026
Ain Shams UniversityNebivolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2HER2-positive Breast CancerFeb 2027
Assaf-Harofeh Medical CenterPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Colorectal NeoplasmsFeb 2027
Actimed TherapeuticsPindolol (ACM-001)
Beta-1 adrenergic receptor partial agonist; Beta-2 adrenergic receptor partial agonist
ADRB1, ADRB2Phase 2ObesityMar 2027
West China Hospitalpropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Infantile HemangiomaMar 2027
AHS Cancer Control AlbertaPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Pancreatic CancerMay 2027
University of AarhusNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 2HypotensionDec 2027
Giuseppe Cullaro, MDDroxidopa
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 2Acute Kidney InjuryDec 2027
Niels JunkerPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Soft Tissue Sarcoma AdultJan 2028
AIDS Malignancy ConsortiumPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Kaposi SarcomaSep 2028
Jeremy Veenstra-vanderweelePropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Autism Spectrum DisorderNov 2028
University of ZurichPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Retinopathy of PrematurityDec 2028
Roswell Park Cancer InstitutePropranolol Hydrochloride
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Esophageal AdenocarcinomaMar 2029
University of AlbertaDobutamine
Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist
ADRB1, ADRB2Phase 2Hypoxic-ischemic Encephalopathy (HIE)Apr 2029
Sherief Abd-ElsalamCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 2Esophageal VaricesDec 2030
Michele Tagliati, MDCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 2REM Sleep Behavior Disorder–
Cedars-Sinai Medical CenterCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 2REM Sleep Behavior Disorder–
Copenhagen University Hospital, RigshospitaletDobutamine
Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist
ADRB1, ADRB2Phase 2Acute Myocardial Infarction–
St. John's Research InstituteNebivolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Diabetic Neuropathy Peripheral–
Tel-Aviv Sourasky Medical CenterPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 2Ovarian Cancer–
Kingston Health Sciences Centredobutamine
Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist
ADRB1, ADRB2Phase 2Shock–
Kingston Health Sciences Centrenorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 2Shock–
Geriatric Hospital of Nanjing Medical UniversityNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 1UrolithiasisDec 2026
University of Alabama at BirminghamLabetalol
Adrenergic receptor antagonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 1Hypertension in PregnancyDec 2026
Second Xiangya Hospital of Central South UniversityPropranolol hydrochloride
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 1Non Small Cell Lung Cancer; Resectable Non-Small-Cell Lung Cancer; Small Cell Lung Cancer (SCLC)Dec 2026
EyeD PharmaTimolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 1GlaucomaJan 2027
Icahn School of Medicine at Mount SinaiTimolol Maleate
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 1Wound HealingJan 2027
Steen Hvitfeldt PoulsenDobutamine
Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist
ADRB1, ADRB2Phase 1ATTR Amyloidosis Wild TypeSep 2027
Sarah WeissPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 1Advanced MelanomaSep 2027
Instituto de Investigación Hospital Universitario La PazDobutamine
Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist
ADRB1, ADRB2Phase 1Infant, Premature, DiseasesJun 2029
Satish R. RajPropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 1TachycardiaDec 2029
Stephen G. KalerDroxidopa
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 1Menkes DiseaseJun 2030
Brigham and Women's HospitalNorepinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 1Hypertension–
Mansoura Universitycarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 1TBI Traumatic Brain Injury–
Mansoura Universitypropranolol
Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist
ADRB1, ADRB2Phase 1TBI Traumatic Brain Injury–

Conditions

Acute Myocardial Infarction (6) Shock (4) Hypotension Drug-Induced (4) Idiopathic Ventricular Fibrillation (4) Septic Shock (3) Pancreatic Cancer (2) Heart Failure With Reduced Ejection Fraction (2) Glaucoma (2) Cesarean Delivery (2) Shock Hypovolemic (2) Cirrhosis (2) Hypotension (2)

Modalities

small molecule (96), mixed (9), protein or peptide (1)

Companies

Mansoura University (4) Bispebjerg Hospital (4) Bo Gregers Winkel (4) Icahn School of Medicine at Mount Sinai (2) Ain Shams University (2) University of Alberta (2) Sherief Abd-Elsalam (2) Dalian Municipal Central Hospital (2) University of Texas Southwestern Medical Center (2) University of California, Davis (2) Damanhour Teaching Hospital (2) Kingston Health Sciences Centre (2) Oslo University Hospital (1) Zealand University Hospital (1) University of Oklahoma (1) Nebraska Methodist Health System (1) Copenhagen University Hospital, Rigshospitalet (1) Fundació d'investigació Sanitària de les Illes Balears (1) Washington University School of Medicine (1) Federal University of São Paulo (1)

Related targets

ADRB2 (86) ADRA1A (42) ADRA2A (32) ADRA2C (30) ADRB3 (13) ADRA1D (13) PTGFR (1) CA2 (1) Ion channels (1) ADRA2B (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.